Skip to Main Content

Advertisement

Skip Nav Destination

Issues

In This Issue

In the Spotlight

Reviews

Research Brief

Intratumoral vidutolimod (CpG-A TLR9 agonist) together with pembrolizumab overcomes PD-1 blockade resistance in 25% of patients with metastatic melanoma with manageable toxicities in a phase I trial.

Research Articles

Analysis of data from the Genomes for Kids research study reveals the value of three-platform whole-genome, wholeexome, and RNA sequencing in identifying clinically and biologically relevant lesions in pediatric cancer.

AKT depletion using a degrader proved superior to kinase inhibition due to sustained repression of AKT signaling and destabilization of AURKB, leading to induction of G2/M arrest, hyperploidy, and cell death.

Reactivation of p53 by MDM2 inhibitors potentiates anticancer immune surveillance through derepression of ERVs and dsRNA stress, resulting in induction of the interferon pathway and improved response to checkpoint therapy.

Genetic screening in a mouse model of biliary cancer revealed Pik3caH1047R activation but not oncogenic KrasG12D as critical for transformation and tumor formation and additionally reveals the context- and tissue-specific nature of oncogenic drivers.

Inhibition of a specific isoform of RON receptor tyrosine kinase (SF-RON) recruits stemlike CD4 T cells to the metastatic site and promotes strong antitumor immune responses that severely restrict growth of breast cancer metastases.

Oncogenic NPM1c mutations prime acute myeloid leukemia cells for mitochondrial targeting by actinomycin D, which restores PML nuclear bodies—driven senescence and is synergistic with venetoclax to induce tumor clearance.

News in Brief

Research Watch

DNA Damage
Tumor Suppressors
Artificial Intelligence
Leukemia
Lymphoma
Microbiome
Breast Cancer
Biotechnology
Epigenetics
Immunology
Targeted Therapy
Clinical Trial
Tumor Microenvironment
Tumorigenesis
Close Modal

or Create an Account

Close Modal
Close Modal